Diagnosing Breast Cancer with Synchronous Metastatic Melanoma
- 1 September 2002
- journal article
- case report
- Published by Wiley in Cancer Practice
- Vol. 10 (5), 224-227
- https://doi.org/10.1046/j.1523-5394.2002.105007.x
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Interferon alfa-2a for melanoma metastasesThe Lancet, 2002
- Quality-of-Life-Adjusted Survival Analysis of High-Dose Adjuvant Interferon Alfa-2b for High-Risk Melanoma Patients Using Intergroup Clinical Trial DataJournal of Clinical Oncology, 2002
- Utilization of Breast-Conserving Surgery in Breast CancerJournal of Clinical Oncology, 2001
- High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801Journal of Clinical Oncology, 2001
- High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696Journal of Clinical Oncology, 2001
- Patient Preferences for Adjuvant Interferon Alfa-2b TreatmentJournal of Clinical Oncology, 2001
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- Vitiligo and melanoma: Can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family?Journal of the American Academy of Dermatology, 1984
- Vitiligo in patients with metastatic melanoma: A good prognostic signJournal of the American Academy of Dermatology, 1983
- High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: A comparison with low-dose fraction therapyCancer, 1982